Study: NCT00613457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Description: 60 mg/sqm p.o. c 28 days in Induction phase 60 mg/sqm p.o. x 56 days in Protocol M 50 mg/sqm daily in Maintenance phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Description: 60 mg/sqm p.o. c 28 days in Induction phase 60 mg/sqm p.o. x 56 days in Protocol M 50 mg/sqm daily in Maintenance phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: by age i.t. in Induction/Protocol M/Protocol II/Protocol III/HR Blocks and maintenance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: by age i.t. in Induction/Protocol M/Protocol II/Protocol III/HR Blocks and maintenance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: by age i.t. in Induction/Protocol M/Protocol II/Protocol III/HR Blocks and maintenance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: by age i.t. in Induction/Protocol M/Protocol II/Protocol III/HR Blocks and maintenance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: by age i.t. in Induction/Protocol M/Protocol II/Protocol III/HR Blocks and maintenance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: by age i.t. in Induction/Protocol M/Protocol II/Protocol III/HR Blocks and maintenance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: by age i.t. in Induction/Protocol M/Protocol II/Protocol III/HR Blocks and maintenance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 60 mg/sqm daily p.o. for 28 days then tapered in Induction phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine
Description: 60 mg/sqm p.o. x 14 days in Protocol II and Protocol III

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine
Description: 60 mg/sqm p.o. x 14 days in Protocol II and Protocol III

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.5 mg/sqm i.v. x 4 doses in Induction phase and Protocol II 1.5 mg/sqm i.v. x 2 doses in Protocol III and HR block 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.5 mg/sqm i.v. x 4 doses in Induction phase and Protocol II 1.5 mg/sqm i.v. x 2 doses in Protocol III and HR block 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.5 mg/sqm i.v. x 4 doses in Induction phase and Protocol II 1.5 mg/sqm i.v. x 2 doses in Protocol III and HR block 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.5 mg/sqm i.v. x 4 doses in Induction phase and Protocol II 1.5 mg/sqm i.v. x 2 doses in Protocol III and HR block 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.5 mg/sqm i.v. x 4 doses in Induction phase and Protocol II 1.5 mg/sqm i.v. x 2 doses in Protocol III and HR block 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.5 mg/sqm i.v. x 4 doses in Induction phase and Protocol II 1.5 mg/sqm i.v. x 2 doses in Protocol III and HR block 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.5 mg/sqm i.v. x 4 doses in Induction phase and Protocol II 1.5 mg/sqm i.v. x 2 doses in Protocol III and HR block 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vindesine
Description: 3 mg/sqm i.v. x 2 doses in HR block 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vindesine
Description: 3 mg/sqm i.v. x 2 doses in HR block 2